Cargando…

Evolution of Quality of Life in Persons with Parkinson’s Disease: A Prospective Cohort Study

Parkinson’s disease (PD) is a chronic neurodegenerative disorder that results in important functional symptoms, altered mood, and deterioration in quality of life (QoL). This study aimed to determine the evolution of the QoL in persons with PD in the Albacete health district over a two-year period a...

Descripción completa

Detalles Bibliográficos
Autores principales: Candel-Parra, Eduardo, Córcoles-Jiménez, María Pilar, Delicado-Useros, Victoria, Hernández-Martínez, Antonio, Molina-Alarcón, Milagros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122703/
https://www.ncbi.nlm.nih.gov/pubmed/33922142
http://dx.doi.org/10.3390/jcm10091824
Descripción
Sumario:Parkinson’s disease (PD) is a chronic neurodegenerative disorder that results in important functional symptoms, altered mood, and deterioration in quality of life (QoL). This study aimed to determine the evolution of the QoL in persons with PD in the Albacete health district over a two-year period and identify associated sociodemographic, clinical, and socio-health characteristics. A cohort study was conducted of patients at different stages of PD in the Albacete health district. Calculated sample size: 155 patients. Instruments: A purpose-designed questionnaire for data collection and the “Parkinson Disease Questionnaire” (PDQ-39), which measures 8 dimensions and a global index where a higher score indicates worse quality of life. Three measurements were made: baseline, one year, two years. A descriptive and bivariate analysis was conducted. Ethical aspects: informed consent, anonymized data. Results: Mean age 69.51 (standard deviation, SD 8.73) years, 60% male, 75.5% married, and 85.5% lived with family. The most frequent motor symptoms were slow movement (86.23%), postural instability (55.5%), tremor (45.5%), and dyskinesia (24.6%). Among the non-motor symptoms were fatigue (66.2%), pain, daytime somnolence, constipation, and apathy, with approximately 50% each. The mean QoL score at baseline was 27.47 (SD 16.14); 95% CI (confidence interval) 24.91–30.03. At two years, global QoL had slightly worsened (28.3; SD 17.26; 95% CI 25.41–31.18), with a statistically significant worsening in mobility, activities of daily living, and communication, whereas social support improved.